SubHero Banner

Fulphila (pegfilgrastim-jmdb) – New biosimilar approval

June 4, 2018 - The FDA announced the approval of Mylan and Biocon’s Fulphila (pegfilgrastim-jmdb), to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Download PDF